{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-024549","form_type":"8-K","ticker":null,"cik":"0001403708","company_name":"Evoke Pharma Inc","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.723465+00:00","generated_at":"2026-06-14T12:43:42.522373+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Evoke Pharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M","bullets":["Stockholders' equity of $2.1M as of March 31, 2023 misses Nasdaq minimum $2.5M requirement.","Company must submit a compliance plan to Nasdaq by July 10, 2023.","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","Failure to regain compliance could lead to delisting from Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-024549","json":"https://secwatch.observer/filing/0000950170-23-024549.json","markdown":"https://secwatch.observer/filing/0000950170-23-024549.md","text":"https://secwatch.observer/filing/0000950170-23-024549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1403708/000095017023024549/0000950170-23-024549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1403708/000095017023024549/evok-20230524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T12:43:42.522373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d5552520b40b8a698b870706efcb7a581597c6b","claim":"Evoke Pharma Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 24, 2023, Evoke Pharma, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based on the Company’s stockholders’ equity of $2.1 million as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2.5 m","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017023024549/0000950170-23-024549-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}